INTRODUCTION
Protein kinase CK2 (an acronym derived from the misnomer ' casein kinase-2 ') is an essential ubiquitous enzyme whose specificity is determined by multiple acidic residues mostly located downstream from the phosphorylatable amino acids [1, 2] . The still increasing list of CK2 substrates includes some 200 proteins, many of which play important roles in a variety of cellular functions, with special reference to signal transduction, gene expression and metabolic regulation (see [1, [3] [4] [5] for reviews). Such a pleiotropic role apparently reflects a high constitutive activity, which, in turn, is suspected to underlie the pathogenic potential of CK2 in oncogenesis and viral infections [5] . The CK2 holoenzyme is composed of two catalytic (α and\or αh) and two β-subunits to form stable heterotetramers. In contrast with other protein kinases sharing a similar hetero-oligomeric structure (e.g. protein kinase A and cyclin-dependent kinases), however, both CK2 holoenzyme and its isolated catalytic subunits have constitutive activity when tested with specific peptide substrates. In i o, however, the situation might be different since the phosphorylation of some CK2 protein targets, exemplified by calmodulin, is inhibited by the β-subunit, whereas other protein substrates rely on the holoenzyme for phosphorylation [3, 6, 7] . This suggests the possibility that a pool of CK2 catalytic subunits is present in the cell, where they play a role distinct from that of the CK2 holoenzyme. In particular, high constitutive activity is conferred to CK2 catalytic subunits by unique interactions between its N-terminal segment and elements of the catalytic core, in particular the activation loop [8, 9] . In the majority of protein kinases this loop includes one or two phosphoacceptor residues whose phosphorylation, either through an autocatalytic event or by an heterologous kinase, is required for activation [10] . Such a regulatory mechanism has never been reported for CK2, whose activation loop does not include either serine or threonine residues. It includes two tyrosine residues, Tyr")# and Tyr")), whose phosphorylation by protein tyrosine kinases has never been shown. CK2 holoenzyme undergoes autophosphorylation at two serine residues (Ser#\Ser$) close to the N-terminus of its β-subunit and, in the presence of polybasic peptides, at serine\threonine residues of the catalytic subunit, which have not been identified [11] . In contrast, the isolated catalytic subunits are devoid of serine\threonine autophosphorylation activity. Recently, evidence has accumulated that, although CK2 is a bona fide serine\threonine kinase, it also displays tyrosine kinase activity under special circumstances [12] [13] [14] . These observations suggest the possibility that autocatalytic phosphorylation of tyrosine residues, especially those implicated in the interaction between the activation loop and the N-terminal segment, might represent a specific regulatory mechanism for CK2 catalytic subunits. The results presented provide new arguments supporting such a hypothesis.
MATERIALS AND METHODS

Materials and enzymes
[γ-$#P]ATP was purchased from Amersham Pharmacia Biotech (San Francisco, CA, U.S.A.). The tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (' PP2 ') and a protease-inhibitor cocktail was obtained from Calbiochem (Darmstadt, Germany) and Boehringer (Mannheim, Germany) respectively. Other reagents were purchased from Sigma (Poole, Dorset, U.K.). 4,5,6,7-Tetrabromobenzo-2-azabenzimidazole (4Br-2-azaBz) was kindly provided by Dr David Shugar (Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland) [15] . Anti-phosphotyrosine was from ICN Biotechnology (Irvine, CA, U.S.A.). Synthetic peptides were synthesized as detailed elsewhere [14, [16] [17] [18] [19] .
Wild-type CK2α, CK2α mutants, CK2αh and CK2β were expressed in Escherichia coli as described elsewhere [19, 20] .
Tyrosine-autophosphorylation of CK2α
CK2α, CK2αh and CK2α mutants (300 nM) were autophosphorylated in 30 µl of incubation medium containing 50 mM Tris\HCl, pH 7.5, 5 mM MgCl # (basal medium) and 0.1 mM ATP. After 20 min of incubation, the reactions were stopped and the samples were subjected to SDS\PAGE. Proteins were transferred to nitrocellulose membranes and immunostained with anti-phosphotyrosine antibodies. Filters were developed using an enhanced chemiluminescence detection system (ECL2 ; Amersham Pharmacia Biotech). Densitometric analysis of the CK2α bands was performed using an ImageMaster VDS instrument (Amersham Pharmacia Biotech).
Autophosphorylation of reconstituted CK2 holoenzyme
Autophosphorylation of CK2 holoenzyme was performed in basal medium containing 50 µM [γ-$#P]ATP and equimolar amounts of CK2α and CK2β (150 nM). After 15 min of incubation, the reactions were stopped and the samples were subjected to SDS\PAGE. The extent of protein $#P phosphorylation was evaluated by analysis on a Packard Imager.
CK2α activity towards a peptide substrate
The standard activity of CK2α and CK2α mutants was tested in basal medium containing 50 µM [γ-$#P]ATP, using the peptide RRRAADSDDDDD (30 µM) as substrate. The reactions were terminated after 5 min of incubation by spotting 25 µl of the mixture on to P81 phosphocellulose papers [22] .
RESULTS
Recombinant human CK2α\αh subunits, expressed in E. coli and purified to near homogeneity, readily undergo tyrosine-autophosphorylation on incubation with ATP and Mg# + , as judged from immunostaining with anti-phosphotyrosine antibodies ( Figure 1, lane 1) . Similar results were obtained by phosphoradiolabelling with [$#P]ATP, followed by alkali treatment to minimize serine\threonine phosphorylation (results not shown). The autocatalytic mechanism of such a tyrosineautophosphorylation process was confirmed by the ability of the specific CK2 co-substrate, GTP, to replace ATP as phosphate donor ( Figure 1 , lane 9), by the failure of a catalytically inactive
Figure 1 Tyrosine-autophosphorylation of CK2α/αh subunits : influence of various compounds
Anti-phosphotyrosine immunostaining of tyrosine-autophosphorylated CK2α (lane 1), CK2αh (CK2' ; lane 2) and CK2α(∆2-12) (lane 3). In lane 4, CK2α (300 nM) and CK2α(∆2-12) (500 nM) were incubated together. In lanes 5-8, tyrosine-autophosphorylation of CK2α was performed in the presence of the following compounds : heparin (1 µg/ml), emodin (5 µM), 4Br-2-azaBz (5 µM) and PP2 (5 µM) respectively. In lane 9, the co-substrate ATP was replaced by GTP as phosphate donor. Tyrosine-autophosphorylation of CK2α/αh subunits was performed and quantified as described in the Materials and methods section. The immunostained band slightly more mobile than CK2α is generated by limited proteolysis of it, as judged by immunoreaction with anti-CK2α antibodies. The mutant, CK2α(∆2-12) (CK2α with residues 2-12 deleted), to undergo tyrosine-autophosphorylation ( Figure 1 , lane 3) and by the effect of specific inhibitors of CK2, such as heparin, emodin and 4Br-2-azaBz, to prevent tyrosine-autophosphorylation of wild-type CK2α at concentrations that are also effective on catalytic activity (Figure 1, lanes 5-7) . In contrast the tyrosine kinase inhibitor PP2 has no effect on CK2α tyrosineautophosphorylation ( Figure 1, lane 8) . Phosphotyrosine incorporation increases more than linearly by increasing the CK2α concentration (Figure 2A ), behaviour which, in conjunction with the inhibitory effect of increasing viscosity by addition of glycerol ( Figure 2B ), argues in favour of an intermolecular (trans), rather than intramolecular (cis) mode of autophosphorylation. Compelling evidence that this must be the case was provided by the behaviour of the intrinsically inactive deletion mutant, CK2α(∆2-12), which is not in itself able to catalyse tyrosineautophosphorylation, but is readily tyrosine-phosphorylated upon incubation with wild-type CK2α (compare lanes 3 and 4 of Figure 1 ).
Interestingly, tyrosine-autophosphorylation is abolished on holoenzyme reconstitution by addition of equimolar concen- tration of the β-subunit to CK2α (Figure 3 ). The addition of synthetic fragments of the β-subunit, which are known to interact with the catalytic subunit, is also detrimental to tyrosineautophosphorylation, although the overall catalytic activity of CK2α is actually enhanced by both the β-subunit and these fragments [18] . The most likely interpretation is that the β-subunit, either directly or by inducing conformational changes, masks the tyrosine residue(s) susceptible to phosphorylation.
A notable feature of CK2α tyrosine-autophosphorylation is its reversal on addition of ADP ( Figure 4A ). In contrast, owing to the difference in energy between the γ-phosphate bond of ATP and the phosphate bond of phosphopeptides, the phosphotransferase reactions catalysed by protein kinases, either serine\ threonine-or tyrosine-specific, are generally not readily reversible. For the sake of comparison, CK2 holoenzyme autophosphorylated at the serine residues of its β-subunits was also incubated with ADP under comparable conditions and, as shown in Figure 4 (B), this treatment did not result in any appreciable loss of radioactivity from the protein. It has to be concluded, therefore, that the phosphotyrosine residues of CK2α are unusually reactive, possibly because they are inside or close to the active site. This conclusion is corroborated by the observation that GDP can replace ADP as phosphate acceptor (Figure 4 ), as would be expected when one considers the unusual ability of CK2 to use GTP as phosphate donor. High reactivity of CK2α phosphotyrosine may account for the failure to find detectable amounts of phosphotyrosine in CK2α recombinantly expressed and purified from bacteria. It may also explain the relatively low level of CK2α tyrosine-autophosphorylation, which, under our conditions, is of relatively low stoichiometry (0.05-0.1 mol of phosphotyrosine\mol of protein).
The unique features of CK2α tyrosine-autophosphorylation are further highlighted by the inhibitory effect of a synthetic peptide, CK2α(175-201), encompassing the whole activation loop ; this peptide is not phosphorylated by CK2α and does not affect either the catalytic activity towards peptide substrates or serine-autophosphorylation of the β-subunit (results not shown). Nevertheless it potently inhibits tyrosine-autophosphorylation with an IC &! around 2.5 µM (see Figure 5 ). This value indicates 
Figure 5 Effect of synthetic peptides on CK2α tyrosine-autophosphorylation
Tyrosine-autophosphorylation of CK2α was evaluated either in the absence (100 %) or presence of increasing concentrations of the indicated peptides. Data are means for three separate experiments. S.E.M. values were always less than 16 %.
an inhibitory efficiency higher than that of the best known CK2 tyrosyl-peptide substrate, derived from the phosphoacceptor site of immunofillin Fpr3, DEDADIYDEEDYDL. This, in turn, is much more effective as an inhibitor of tyrosineautophosphorylation than the optimal seryl-peptide substrate RRRADDSDDDDD (IC &! values 11 µM versus 40 µM), despite its K m value is huge as compared with that of the seryl peptide (384 µM versus 20 µM) [13] . We conclude, therefore, that inhibition of tyrosine-autophosphorylation by the activation loop (175-201) peptide is not merely a consequence of substrate competition, but reflects specific interactions relevant only to tyrosine-autophosphorylation.
Since the activation loop of CK2 includes two tyrosine residues (Tyr")# and Tyr"))), one of which makes crucial interactions with
Figure 6 Mutation of Tyr 182 to phenylalanine suppresses tyrosineautophosphorylation of CK2α
Tyrosine residues implicated in the interaction between the activation loop (light grey) and the N-terminal segment (dark grey) are shown. The Figure is drawn from the crystal structure of maize CK2α [8] using Raster3D and MOLSCRIPT programs [33, 34] . The inset shows the antiphospho-Tyr immunostaining of tyrosine-autophosphorylated wild-type CK2α and the indicated mutants. The catalytic activity of the mutants, tested toward the peptide RRRAADSDDDDD and expressed relative to wild-type CK2α (l 100) is indicated in parentheses.
the activatory N-terminal segment, and, in turn, a tyrosine residue of the N-terminal segment (Tyr#') hydrogen bonds with Glu")! in the activation loop (see Figure 6 ) these three tyrosine residues were individually mutated to phenylalanine to assess their possible implication in the autophosphorylation event. All these mutants are catalytically active, albeit less than wildtype CK2α. As shown in the inset of Figure 6 , however, the mutant Y182F totally lost its ability to undergo tyrosineautophosphorylation. These data strongly suggest that Tyr")# is the main, if not the only, site of tyrosine-autophosphorylation in wild-type CK2α. However, indirect effects cannot be excluded, and they could account for the inability of the mutant Y182F to autophosphorylate even if the target tyrosine residue is present in its sequence.
DISCUSSION
The data presented provide evidence that, in the presence of ATP (or GTP) and Mg# + , both catalytic subunits of CK2, α and αh, undergo appreciable autophosphorylation at tyrosine residue(s), one of which is, most likely, Tyr")#, located in the activation loop. The autocatalytic occurrence of CK2α\αh tyrosinephosphorylation is consistent with all the available data ; in particular, it is susceptible to competitive inhibition by the specific peptide substrates RRRADDSDDDDD and DEDADIYDEEDYDL and it is strictly dependent on intrinsic catalytic activity, being reduced or abolished by specific CK2 inhibitors and by a mutation that suppresses CK2α enzymic activity. A trans (intermolecular) rather than a cis (intramolecular) autocatalytic mechanism appears to underlie CK2α tyrosine-phosphorylation, since its rate increases more than linearly by increasing CK2α concentration and decreases to negligible values if the viscosity of the incubation medium is increased with glycerol. Consequently, an intrinsically inactive mutant of CK2α that is not itself able to undergo tyrosineautophosphorylation, namely CK2α(∆2-12), becomes readily tyrosine-phosphorylated upon incubation with wild-type CK2α.
Although CK2α\αh tyrosine-autophosphorylation is an intermolecular event depending on catalytic activity, it appears to be unique in several respects. First, it is prevented by association with the β-subunit, which is conversely required for serine\ threonine-autophosphorylation of CK2 holoenzyme either in the absence or presence of polybasic peptides and generally increases catalytic activity toward most, albeit not all, CK2 targets. Secondly, tyrosine-autophosphorylation is readily reversed in the presence of an excess of the phosphoacceptor co-substrate ADP, whereas serine-autophosphorylation of CK2 holoenzyme is not. Thirdly, tyrosine-autophosphorylation is efficiently and specifically inhibited by micromolar concentration of the peptide CK2α(175-201) reproducing the activation loop of CK2α, although this peptide has no effect on catalytic activity (tested with the specific peptide substrate) nor on serineautophosphorylation of the holoenzyme (results not shown). What makes inhibition of tyrosine-autophosphorylation by CK2α(175-201) intriguing is, on the one hand the inhibitory potency of the peptide, by far superior to that of the optimal CK2 peptide substrate RRRADDSDDDDD, and, on the other hand, its failure to undergo phosphorylation by CK2 at any of its tyrosine residues. In a way this latter outcome did not come as a surprise, since none of the tyrosine residues in the CK2α(175-201) peptide displays the consensus for tyrosylpeptide phosphorylation by CK2 [13] . This, however, also applies to all the tyrosine residues of CK2α. Taken collectively, these data would indicate that inhibition of tyrosine-autophosphorylation by the CK2α(175-201) peptide cannot be explained by substrate competition alone and must involve specific interactions that do not affect the regular catalytic activity of the enzyme. On the other hand, the identification of one of the tyrosine residues included in the CK2α(175-201) peptide, Tyr")#, a strong candidate to be the main, if not the only, tyrosine residue modified by autophosphorylation of full-length CK2α, is soundly grounded on the observation that its mutation to phenylalanine is sufficient to fully abolish tyrosine-autophosphorylation, although the catalytic activity of this mutant is comparable with that of other mutants (e.g. Y26F) whose tyrosineautophosphorylation is unaffected. It has to be assumed, therefore, that autophosphorylation of Tyr")# within the α-subunit is dictated by conformational features that are missing in the synthetic peptide spanning residues 175-201. This region corresponds to the so-called ' activation loop ', whose phosphorylation in most protein kinases is a prerequisite for attainment of a fully active conformation [10] . In this respect, however, CK2 represents an exception, since its active conformation does not rely on previous phosphorylation of its activation loop but is provided by extensive interaction between the activation loop and the Nterminal segment [8, 9] . The sequence homologue of the residue whose phosphorylation triggers the activation of other kinases (protein kinase A Thr"*() in CK2α is Asn")*, a residue quite a long way away from Tyr")#. The side chain of this latter, moreover, is oriented in a direction opposite to the catalytic site, being engaged with the N-terminal tail, through a hydrogen bond with the backbone nitrogen atom of Ala* (see Figure 6) . Incidentally, the relevance of this interaction to active conformation is confirmed by the reduced catalytic activity of the Y182F mutant (inset to Figure 6 ). One might expect, therefore, that phosphorylation of Tyr")# will lead to down-regulation of CK2α\αh by weakening the overall interaction between the activation loop and the N-terminal segment. Experimental support for this hypothesis could not be provided up until now, owing to the low stoichiometry of CK2α\αh tyrosineautophosphorylation and the failure to achieve a satisfactory separation of the phosphorylated from unphosphorylated form of the kinase by immunoprecipitation with anti-phosphotyrosine antibody. This may be a consequence of the instability of this tyrosine-phosphate linkage, consistent with the reversal of the autophosphorylation reaction observed in the presence of ADP (see Figure 4A) .
While the physiological relevance of CK2 tyrosine autophosphorylation is a matter of conjecture, the available data are consistent with a scenario whereby the overall activity of intracellular CK2 catalytic subunits is determined by the balance between Tyr")# autophosphorylation and -dephosphorylation, the former prevailing over the latter only under conditions where CK2α\αh concentration becomes exceedingly high (e.g. in special subcellular compartments) and the ATP\ADP ratio is also high. From our in itro experiments it would appear that the majority of CK2 molecules, present in the cell as heterotetrameric holoenzyme, are refractory to this mode of regulation. This might conversely play a critical role in down-regulating pools of free CK2 catalytic subunits, whose presence in living cells is made plausible by a number of observations (see, e.g. [23] [24] [25] [26] ), and which under certain experimental conditions, such as transgenic mice [27] [28] [29] and cultured cells transfected with CK2α\αh [30, 31] is suspected to display oncogenic potential. Pertinent to this may also be the observation that tyrosine-phosphorylation of CK2α co-transfected with p190Brc-Abl in NIH3T3 cells correlates with a decrease in catalytic activity [32] . It will be important to assess whether, in this case also, Tyr")# is involved and\or if the same residue can be phosphorylated in itro by Abl and possibly by other protein-tyrosine kinases as well.
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